【摘要】 目的:评价6种用药方案治疗原发性高血压的成本-效果。方法:将720例原发性高血压患者随机分为6组,A、B组分别给予国产与进口苯磺酸氨氯地平(5mg,qd),C、D组分别给予国产与进口盐酸贝那普利(10mg,qd),E组给予国产苯磺酸氨氯地平(5mg,qd)与盐酸贝那普利(10mg,qd),F组给予进口苯磺酸氨氯地平(5mg,qd)与盐酸贝那普利(10mg,qd),均治疗12周,观察各组疗效及不良反应,并运用药物经济学原理进行成本-效果分析。结果:A、B、C、D、E、F组总有效率分别为68.3%、70.0%、67.5%、68.3%、91.7%、92.5%,A、B、C、D组间总有效率差异无统计学意义(P>0.05),E、F组总有效率差异无统计学意义(P>0.05),但E、F组总有效率分别与A、B、C、D组比较差异具有统计学意义(P<0.05);6组药品不良反应发生率差异无统计学意义(P>0.05)。A、B、C、D、E、F组成本分别为83.16、429.24、204.96、332.64、288.12、761.88元,成本-效果比分别为121.76、613.20、303.64、487.03、314.20、823.65;B、E、F组相对于A组的增量成本-效果比分别为20357.65、875.90、2804.63。结论:国产苯磺酸氨氯地平片与盐酸贝那普利片或者两者联合用药治疗原发性高血压的疗效与相应进口制剂无明显差异,但应用国产制剂组药品费用与成本-效果比明显低于应用进口制剂组(P<0.05),其治疗原发性高血压的经济学效果优于进口品种。更多还原

【Abstract】 OBJECTIVE: To compare the cost-effectiveness among 6 therapeutic schemes in treating patients with essential hypertension. METHODS: 720 patients with essential hypertension were randomized into 6 groups of 120 each: Group A received domestic amlodipine besylate (5 mg qd), Group B imported amlodipine besylate (5 mg qd), Group C domestic benazepril hydrochloride (10 mg qd), Group D imported benazepril hydrochloride (10 mg qd), Group E domestic amlodipine besylate (5 mg qd) plus domestic benazepril hydrochloride (10 mg qd), and Group F imported amlodipine besylate (5 mg qd) plus imported benazepril hydrochloride (10 mg qd). After treatment for 12 weeks for all groups, the curative effects and adverse drug reactions (ADR) were monitored and the cost-effectiveness analysis were conducted using the principle of pharmacoeconomics. RESULTS: The total effective rates of the 6 groups were 68.3%, 70.0%, 67.5%, 68.3%, 91.7% and 92.5%, respectively, showing no significant differences across Group A, B, C and D (P>0.05) or between Group E and Group F (P>0.05), but there were significant differences between Group E and the other 4 groups (Group A, B, C and D) or between Group F and the other 4 groups (Group A, B, C and D) in the total effective rates (P<0.05). However, the differences in ADRs were nonsignificant across the 6 groups (P>0.05). The costs in the 6 groups were 83.16 yuan, 429.24 yuan, 204.96 yuan, 332.64 yuan, 288.12 yuan and 761.88 yuan, respectively, and the cost-effectiveness ratios were 121.76, 613.20, 303.64, 487.03, 314.20 and 823.65, respectively. The incremental cost-effectiveness ratios in Group B, E and F were 20 357.65, 875.90 and 2 804.63, respectively as against Group A. CONCLUSIONS: The domestic amlodipine besylate and domestic benazepril hydrochloride tablets used either alone or in combination are as effective as the imported counterparts but significantly lower in drug costs and cost-effectiveness ratios than the imported counterparts (P<0.05), thus it is superior to the imported counterparts in economical outcome in the treatment of patients with essential hypertension.更多还原